Rivastigmine transdermal patch: a guide to its use in dementia of the Alzheimer’s type

[1] Yang L.P.H.(2007)Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer’s type CNS Drugs 21 957-65

[2] Keating G.M.(2004)Management of mild to moderate Alzheimer disease Dis Manage Health Outcomes 12 55-72

[3] Plosker G.L.(2006)Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease Am J Geriatr Psychiatry 14 561-73

[4] Keating G.M.(2007)Rivastigmine exposure provided by a transdermal patch versus capsules Curr Med Res Opin 23 3199-204

[5] Lyketsos C.G.(2007)A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch Curr Med Res Opin 23 2705-13

[6] Colenda C.C.(2007)A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease: rivastigmine patch versus capsules Int J Geriatr Psychiatry 22 456-67

[7] Beck C.(2007)Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease Int J Geriatr Psychiatry 22 485-91

[8] Mercier F.(2007)Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application J Clin Pharmacol 47 471-8

[9] Lefèvre G.(2000)Lack of adverse pharmacodynamic drug interactions with rivastigmine and twentytwo classes of medications Int J Geriatr Psychiatry 15 242-7

[10] Huang H.L.A.(2007)IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease Neurology 69 S14-22

[1] Yang L.P.H.(2007)Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer’s type CNS Drugs 21 957-65

[2] Keating G.M.(2004)Management of mild to moderate Alzheimer disease Dis Manage Health Outcomes 12 55-72

[3] Plosker G.L.(2006)Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease Am J Geriatr Psychiatry 14 561-73

[4] Keating G.M.(2007)Rivastigmine exposure provided by a transdermal patch versus capsules Curr Med Res Opin 23 3199-204

[5] Lyketsos C.G.(2007)A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch Curr Med Res Opin 23 2705-13

[6] Colenda C.C.(2007)A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease: rivastigmine patch versus capsules Int J Geriatr Psychiatry 22 456-67

[7] Beck C.(2007)Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease Int J Geriatr Psychiatry 22 485-91

[8] Mercier F.(2007)Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application J Clin Pharmacol 47 471-8

[9] Lefèvre G.(2000)Lack of adverse pharmacodynamic drug interactions with rivastigmine and twentytwo classes of medications Int J Geriatr Psychiatry 15 242-7

[10] Huang H.L.A.(2007)IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease Neurology 69 S14-22